News for Mirum Pharmaceuticals, Inc. (MIRM)

Evercore ISI has increased its price target for Mirum Pharmaceuticals (MIRM), lifting it from $68 to $76 while maintaining an Outperform rating. This adjustment

Summary Mirum Pharmaceuticals Inc (MIRM), a biopharmaceutical company focused on treating rare diseases, announced on July 10, 2025, that its Compensation Commi

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on July 10, 2025, the Compensation Committee of Mirum's Board of Directors granted inducement a

On June 11, 2025, William Fairey, Director at Mirum Pharmaceuticals Inc (MIRM), sold 3,203 shares of the company, according to a SEC Filing. Following this tran

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mirum Pharmaceuticals, known by its ticker MIRM, has appointed Doug Sheehy as its new Chief Legal Officer. Before joining Mirum, Sheehy served as the Chief Lega

Summary Mirum Pharmaceuticals Inc (MIRM) announced the appointment of Doug Sheehy, JD, as the new chief legal officer. With nearly two decades of experience in

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of

Mirum Pharmaceuticals (MIRM) appoints Doug Sheehy as Chief Legal Officer. Doug Sheehy brings extensive legal experience from Sonoma Biotherapeutics, Aim

H.C. Wainwright has initiated coverage on Mirum Pharmaceuticals (MIRM) with a Buy rating and set a price target of $73. Mirum is known for its work in developin

Operator: Hello and welcome to Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results. My name is Carla, and I'll be coordinating your call today.

Mirum Pharmaceuticals (MIRM) has received an update from analyst Steven Seedhouse at Raymond James. The analyst maintains a "Strong Buy" rating on the stock, re

Mirum Pharmaceuticals (MIRM) continues to receive a Buy rating from Citi, with a target price set at $72. This comes in light of the company's recent interim re

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on May 9, 2025, the Compensation Committee of Mirum's Board of Directors granted inducement awa

On May 9, 2025, JMP Securities analyst Jonathan Wolleben reaffirmed a 'Market Outperform' rating for Mirum Pharmaceuticals (MIRM). The analyst maintained the po

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ETCompany ParticipantsAndrew McKibben - SVP, Strategic...

[url="]Clearwater Analytics Holdings, Inc[/url][url="].[/url] (NYSE: CWAN) (”œClearwater Analytics” or the ”œCompany”), the most comprehensive technology

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2025 financial results on Wednesday, May 7, 2025. Mirum will also

Mirum Pharmaceuticals (MIRM) to report Q1 2025 financial results on May 7, 2025. Conference call scheduled on the same day at 4:30 p.m. ET. Replay av